Clopidogrel

ATC CODE

  • B01AC04

INDICATIONS AND NEMLC RECOMMENDATIONS

INDICATIONS AND NEMLC RECOMMENDATIONS 1

INDICATION

  • Percutaneous coronary intervention (stenting).

NEMLC RECOMMENDATION

  • Approved
    Clopidogrel plus aspirin recommended for a minimum of:
    • 30 days in situations where a bare metal stent is inserted.
    • 90 days in situations where a sirolimus drug-eluting stent is inserted.
    • 180 days when a paclitaxel drug-eluting stent is inserted.

Thereafter allow aspirin indefinitely.
The evidence currently available to the Committee does not provide support for use beyond 6 months although there are recommendations endorsing longer term use in high risk patients

DATE RATIFIED

  • 20 September 2007


INDICATIONS AND NEMLC RECOMMENDATIONS 2

INDICATION

  • Ischaemic heart disease (non myocardial infarction)

NEMLC RECOMMENDATION

  • Approved
    For use only in patients intolerant to aspirin, i.e. allergy or bleeding episodes.

DATE RATIFIED

  • 20 September 2007


INDICATIONS AND NEMLC RECOMMENDATIONS 3

INDICATION

  • Stroke.

NEMLC RECOMMENDATION

  • Approved, only for long-term therapy where patient has confirmed aspirin intolerance.

REVIEW INDICATORS

  • Decrease in clopidogrel price
  • New safety or efficacy data for either aspirin (at doses recommended by the DoH) or clopidogrel

DATE RATIFIED

  • 24 July 2014

INDICATIONS AND NEMLC RECOMMENDATIONS 4

INDICATION

  • Transient ischaemic attack with/without atrial fibrillation.

NEMLC RECOMMENDATION

  • Not Approved

REVIEW INDICATORS

  • Decrease in clopidogrel price
  • New safety or efficacy data for either aspirin or clopidogrel

DATE RATIFIED

24 July 2014